Hyderabad-based vaccines and biotherapeutics manufacturer Bharat Biotech International said on Wednesday that its anti-staphylococcal molecule Lysostaphin had secured patent rights in US, Europe, China, Australia and other nations.
Lysostaphin is a potent anti-staphylococcal therapeutic with a targeted specificity against staphylococcus aureus, which causes a range of diseases including wound infections, systemic and life-threatening conditions (endocarditis), osteomyelitis, pneumonia, brain abscesses, meningitis and bacteremia, food poisoning, scalded skin syndrome and toxic shock syndrome.
Krishna Ella, chairman and managing director, said the patent rights for lysostaphin was a significant milestone in the company’s new therapeutic product development programme and would pave the way to develop products for regulated markets in addition to India. A pre-investigational new drug (IND) application meeting of the pre-clinical data has already been held with US FDA, he said.
Lysostaphin is bactericidal and is indifferent to antibiotic resistance. This is the first biotech product molecule patent by an Indian company.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.